ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OCS vs INDP // OPERATING MARGIN

Oculis Holding AG (NASDAQ) VS. Indaptus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OCS 0 — INDP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCS VS. INDP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OCS INDP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -2.89% — TIE /fcf-yield <GO>
Operating Margin ACTIVE — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 2/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.6 54.2 -8.57 INDP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $507.5M $513.0M -$5.5M INDP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OCS REV INDP REV OCS GROSS % INDP GROSS % OCS FCF INDP FCF
FY 2025 — $0 — — — -$14.8M
FY 2024 — $0 — — — -$12.3M
FY 2023 — $0 — — — -$13.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCS // BETA —
INDP // BETA —